Know Cancer

forgot password

LUX Lung 2 A Phase II Single Arm Study of BIBW 2992 in NSCLC Patients Who Have Failed One Line of Chemotherapy or Are Chemotherapy Naive and Who Have EGFR Activating Mutations.

Phase 2
18 Years
Open (Enrolling)
Carcinoma, Non-Small-Cell Lung

Thank you

Trial Information

LUX Lung 2 A Phase II Single Arm Study of BIBW 2992 in NSCLC Patients Who Have Failed One Line of Chemotherapy or Are Chemotherapy Naive and Who Have EGFR Activating Mutations.

Inclusion Criteria

Inclusion criteria:

1. Patients with pathologically confirmed diagnosis of NSCLC Stage IIIB (with pleural
effusion) adenocarcinoma or Stage IV adenocarcinoma.

2. Presence of activating mutation(s) in exon 18 to exon 21 of the EGFR-receptor
confirmed by direct DNA sequencing of NSCLC tumor tissue.

3. Progressive disease following a first line cytotoxic chemotherapy regimen or have
recurrent disease after prior neoadjuvant or adjuvant chemotherapy. Patients who have
not received first-line cytotoxic chemotherapy can be enrolled in stage 2 of the
trial, if the criteria for entering stage 2 are met.

4. Patients with at least one tumor lesion that can accurately be measured by computed
tomography (CT) or magnetic resonance imaging (MRI) in at least one dimension with
longest diameter to be recorded as 20 mm using conventional techniques or 10 mm with
spiral CT scan.

5. Male or female patient aged 18 years.

6. Life expectancy of at least three (3) months.

7. Written informed consents that is consistent with ICH-GCP guidelines.

8. Eastern Cooperative Oncology Group (ECOG) performance score 0, 1 or 2.

Exclusion criteria:

1. More than one (1) prior cytotoxic chemotherapy treatment regimen for relapsed or
metastatic NSCLC.

2. Chemo-, hormone- (other than Megace®) or immunotherapy within the past 4 weeks or
within less than four half-lives of the previous drug prior to treatment with the
trial drug and/or persistence of toxicities of prior anticancer therapies which are
deemed to be clinically relevant.

3. Previous treatment with erlotinib (Tarceva®), gefitinib (Iressa®) or any other EGFR
inhibiting small molecule or antibody.

4. Brain metastases, which are symptomatic; patients with treated, asymptomatic brain
metastases are eligible with stable brain disease for at least four (4) weeks without
the requirement for steroids or anti-epileptic therapy.

5. Significant or recent acute gastrointestinal disorders with diarrhea as a major
symptom e.g., Crohns disease, malabsorption, or CTCAE Grade >2 diarrhea of any
etiology at baseline.

6. Patients who have any other life-threatening illness or organ system dysfunction,
which in the opinion of the investigator, would either compromise patient safety or
interfere with the evaluation of the safety of the test drug.

7. Other malignancies diagnosed within the past five (5) years (other than
non-melanomatous skin cancer and in situ cervical cancer).

8. Radiotherapy within the past 2 weeks prior to treatment with the trial drug.

9. Patients with any serious active infection (i.e., requiring an IV antibiotic,
antifungal, or antiviral agents).

10. Patients with known HIV, active hepatitis B or active hepatitis C.

11. Known or suspected active drug or alcohol abuse.

12. Women of child-bearing potential or men who are able to father a child unwilling to
use a medically acceptable method of contraception during the trial.

13. Pregnancy or breast feeding.

14. Patient unable to comply with the protocol.

15. History of clinically significant or uncontrolled cardiac disease, including
congestive heart failure, angina, myocardial infarction, arrhythmia, including New
York Heart Association (NYHA) functional classification of 3.

16. Cardiac left ventricular function with resting ejection fraction of less than 50%
measured by multigated blood pool imaging of the heart (MUGA scan) or echocardiogram.

17. QTc interval greater than 0.47 second.

18. Prior treatment with anthracyclines with a cumulative dose of doxorubicin (or
equivalent) greater than 400 mg/m2.

19. Absolute neutrophil count (ANC) less than 1500/mm3.

20. Platelet count less than 100 000 /mm3.

21. Bilirubin greater than 1.5 mg / dl (greater than 26 micromol / L, SI unit

22. Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than
three times the upper limit of normal (if related to liver metastases greater than
five times the upper limit of normal).

23. Serum creatinine greater than 1.5 times of the upper normal limit or
calculated/measured creatinine clearance equal or less than 45 ml / min.

24. Patients with known pre-existing interstitial lung disease

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Objective response (CR, PR) as determined by RECIST

Outcome Time Frame:

Response assessment is done at completion of week 4, 8 and 12, and at 8-weeks intervals thereafter.

Safety Issue:


Principal Investigator

Boehringer Ingelheim

Investigator Role:

Study Chair

Investigator Affiliation:

Boehringer Ingelheim Pharmaceuticals


Taiwan: Department of Health, Executive Yuan, Taiwan

Study ID:




Start Date:

August 2007

Completion Date:

July 2013

Related Keywords:

  • Carcinoma, Non-Small-Cell Lung
  • Carcinoma
  • Carcinoma, Non-Small-Cell Lung



1200.22.28 Boehringer Ingelheim Investigational Site Bakersfield, California  
1200.22.32 Boehringer Ingelheim Investigational Site Beverly Hills, California  
1200.22.4 Boehringer Ingelheim Investigational Site Mission Hills, California  
1200.22.16 Boehringer Ingelheim Investigational Site Orange, California  
1200.22.19 Boehringer Ingelheim Investigational Site Fort Lauderdale, Florida  
1200.22.29 Boehringer Ingelheim Investigational Site North Miami Beach, Florida  
1200.22.10 Boehringer Ingelheim Investigational Site Atlanta, Georgia  
1200.22.18 Boehringer Ingelheim Investigational Site Chicago, Illinois  
1200.22.3 Boehringer Ingelheim Investigational Site Bethesda, Maryland  
1200.22.14 Boehringer Ingelheim Investigational Site Boston, Massachusetts  
1200.22.24 Boehringer Ingelheim Investigational Site Flint, Michigan  
1200.22.5 Boehringer Ingelheim Investigational Site Minneapolis, Minnesota  
1200.22.15 Boehringer Ingelheim Investigational Site New York, New York  
1200.22.26 Boehringer Ingelheim Investigational Site New York, New York  
1200.22.1 Boehringer Ingelheim Investigational Site Rochester, New York  
1200.22.27 Boehringer Ingelheim Investigational Site Syracuse, New York  
1200.22.25 Boehringer Ingelheim Investigational Site Valhalla, New York  
1200.22.6 Boehringer Ingelheim Investigational Site Canton, Ohio  
1200.22.7 Boehringer Ingelheim Investigational Site Wynnewood, Pennsylvania  
1200.22.22 Boehringer Ingelheim Investigational Site Mt. Pleasant, South Carolina  
1200.22.31 Boehringer Ingelheim Investigational Site Fairfax, Virginia  
1200.22.40 Boehringer Ingelheim Investigational Site Renton, Washington  
1200.22.33 Boehringer Ingelheim Investigational Site Seattle, Washington